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(Correspondence should be addressed to E R Maher; Email: e.r.maher@bham.ac.uk)AbstractThe molecular genetics of inherited phaeochromocytoma have received considerable attention,
but the somatic genetic and epigenetic events that characterise tumourigenesis in sporadic
phaeochromocytomas are less well defined. Previously, we found considerable overlap between
patterns of promoter region tumour suppressor gene (TSG) hypermethylation in two neural crest
tumours, neuroblastoma and phaeochromocytoma. In order to identify candidate biomarkers and
epigenetically inactivated TSGs in phaeochromocytoma and neuroblastoma, we characterised
changes in gene expression in three neuroblastoma cell lines after treatment with the
demethylating agent 5-azacytidine. Promoter region methylation status was then determined for
28 genes that demonstrated increased expression after demethylation. Three genes HSP47,
homeobox A9 (HOXA9) and opioid binding protein (OPCML) were methylated in O10% of
phaeochromocytomas (52, 17 and 12% respectively). Two of the genes, epithelial membrane
protein 3 (EMP3) and HSP47, demonstrated significantly more frequent methylation in
neuroblastoma than phaeochromocytoma. These findings extend epigenotype of phaeochromo-
cytoma and identify candidate genes implicated in sporadic phaeochromocytoma tumourigenesis.Endocrine-Related Cancer (2008) 15 777–786Introduction
Neuroblastoma and phaeochromocytoma are the com-
monest neural crest-derived tumours in children and
adults respectively. Most phaeochromocytomas are
benign catecholamine-producing tumours arising within
the adrenal medulla, but may be extra-adrenal (when they
may be designated as paragangliomas) and/or approxi-
mately malignant (Chrisoulidou et al. 2007, Disick &
Palese 2007). Up to one-third of phaeochromocytomasEndocrine-Related Cancer (2008) 15 777–786
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2001a,b, Neumann et al. 2002, Gimenez-Roqueplo
2006). Inherited predisposition to phaeochromocytoma
may be associated with mutations in NF1, RET, SDHB,
SDHC, SDHD or VHL genes, but somatic mutations in
VHL, RET, NF1, SDHB and SDHD are rare in sporadic
phaeochromocytomas (Eng et al. 1995, Hofstra et al.
1996, Astuti et al. 2001b,c, 2003). Promoter region
hypermethylation and transcriptional silencing is aBritain
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C D E Margetts et al.: Evaluation of a functional epigenetic approachfrequent cause of tumour suppressor gene (TSG)
inactivation in many human cancers. Previously, in
order to identify candidate epigenetically inactivated
TSGs in phaeochromocytoma, we analysed promoter
methylation status in a series of candidate genes known to
undergo epigenetic silencingand foundsimilar patternsof
promoter hypermethylation in neuroblastoma and phaeo-
chromocytoma. Thus, TSP1,CASP8,HIC1,DcR1,DcR2
andDR4 andRASSF1weremethylated frequently in both
tumour types (Astuti et al. 2001c,Margetts et al. 2005). In
contrast to phaeochromocytoma, familial neuroblastoma
is rare. However, the genetic and epigenetic events
associated with tumourigenesis in sporadic neuroblas-
toma are better defined than in phaeochromocytoma and
molecular investigations of phaeochromocytoma tumour-
igenesis have been hampered by the absence of a human
phaeochromocytoma cell line.
Based on our previous studies, we hypothesised that
the identification of novel genes exhibiting promoter
methylation in neuroblastoma would also provide
plausible candidate genes for phaeochromocytoma
tumourigenesis. In order to expand the number of
candidate ‘epigenetically silenced TSGs’, we investi-
gated a functional epigenomic approach (Alaminos
et al. 2005) in neuroblastoma cell lines in order to
identify candidate epigenetically inactivated TSGs in
neuroblastoma and phaeochromocytoma.Patients and methods
Patients and samples
DNA from a total of 52 tumour samples were analysed
(19 NB’s, 19 VHL-associated phaeochromocytomas and
14 sporadic phaeochromocytomas). Informed consent
and approval from the appropriate Institutional Review
Boardswereobtained for all samples.DNAwas extracted
by standard methods. Normal human adult adrenal
cDNA and genomic DNA were obtained from AMS
Biotechnology (Europe) Ltd (Abingdon, Oxon, UK).Cell lines
The ten neuroblastoma cell lines used were SK-N-AS,
SK-N-F1, SK-N-DZ, SK-N-MC, SK-N-BE, SK-N-SH,
NMB and LAN-5 (American Type Culture Collection,
Manassas, VA, USA), KELLY and CHP212.Sodium bisulphate modification
Sodium bisulphite modification was carried out using
an adapted method (Herman et al. 1996). Genomic
DNA (0.5–1.0 mg) was denatured at 37 8C for 10 min in
0.3 MNaOH. Unmethylated cytosines were sulphonated778by incubation in 3.12 M sodium bisulphite and 1 M
hydroquinone (pH 5) at (95 8C (30 s) 50 8C (15 min)) for
20 cycles. The resulting sulphonated DNA was purified
using the Wizard DNA clean-up system (Promega),
according to the manufacturer’s instructions, except that
DNA was eluted with distilled water (50 ml) at room
temperature. Following elution, DNA was desulpho-
nated in 0.3 M NaOH for 5 min at room temperature,
then theDNAwas precipitatedwithNaOAc (5 ml of 3 M)
and ethanol (125 ml of 100%) overnight atK20 8C and
resuspended in 50 ml distilled water.Direct bisulphate DNA sequencing and
methylation-specific PCR (MSP)
We determined CpG island methylation status by
direct sequencing of bisulphite-modified genomic
DNA or MSP.
For direct bisulphite sequencing, PCR products were
excised from agarose gels and extracted using the
QIAquick Gel Extraction kit (Qiagen), according to the
manufacturer’s instructions. Products were confirmed
by direct sequencing from the forward or reverse PCR
primer using ABI PRISM BigDye Terminator v3.1
Cycle sequencing kit (Genpak Ltd, Brighton, Sussex,
UK) according to the manufacturer’s instructions and
run using ABI PRISM 3700 automatic sequencer (See
Supplementary Table 1 which can be viewed online at
http://erc.endocrinology-journals.org/supplemental/
for primers and PCR conditions).
MSP was performed essentially using previously
published primers and conditions (Conway et al. 2000,
Sellar et al. 2003, Yang et al. 2004, Alaminos et al. 2005,
Breault et al. 2005, Lind et al. 2006). Expected PCR
products are as follows: forHSP47(a), 134 (methylated)/
135 (unmethylated) bp;HSP47(b), 109 (methylated)/110
(unmethylated) bp; EMP3, 252 (methylated)/255
(unmethylated) bp; opioid binding protein (OPCML),
135 (methylated)/135 (unmethylated) bp; CTNNG, 95
(methylated)/85 (unmethylated) bp; SYK, 242 (methyl-
ated)/140 (unmethylated); TMS1, 212 (methylated)/209
(unmethylated) bp; Homeobox A9 (HOXA9), 127
(methylated)/139 (unmethylated) bp (see Supplementary
Table 1 which can be viewed online at http://erc.
endocrinology-journals.org/supplemental/).
Reactions were hot-started at 95 8C for 15 min, by
using 0.25 ml (5 units/ml) of HotstarTaq DNA poly-
merase (Qiagen). PCR products were visualised on 2%
agarose gels stained with ethidium bromide. Genomic
DNA methylated in vitro using SssI methylase (New
England Biolabs, Ipswich, MA, USA) was used as a
positive control for MSP and direct bisulphite
sequencing.www.endocrinology-journals.org
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5-aza-2 0-deoxycytidine
5-aza-2 0-deoxycytidine (5-aza-dC, Sigma) was freshly
prepared in ddH2O at 2 mg/ml and filter sterilised.
Cells (1!106) were plated in 75 cm2 flask in RPMI
1640 medium supplemented with 10% FCS and left to
settle for 24 h (day 0). Cells were treated with 2 mM of
5-aza-dC at days 1 and 4 and harvested at day 5. The
culture medium was changed before each treatment
and 24 h after treatment. Total RNA was extracted
using the RNeasy kit (Qiagen) according to the
manufacturer’s guidelines.U133A Plus Affymetrix oligonucleotide array
analysis of neuroblastoma cell lines and gene
expression analysis
Total RNA was isolated from the 5-aza-dC-treated and
untreated neuroblastoma cell lines (SK-N-F1, SK-N-BE
and SK-N-DZ) using the RNeasy Mini kit (Qiagen) and
subsequently cleaned using the RNeasy mini columns
(Qiagen) according to manufacturer’s instructions. The
quality and integrity of the RNA was verified by
checking 28S and 18S rRNA after ethidium bromide
staining of total RNA samples on 1% agarose gel
electrophoresis. cDNA was performed using the
SuperScript Double Stranded cDNA Synthesis kit
(Invitrogen). cRNA was synthesised by in vitro
transcription with biotinylated UTP and CTP. Labelled
nucleic acid target quality was assessed by test 2 arrays
and hybridised (45 8C for 16 h) to Affymetrix Human
U133A plus oligonucleotide arrays. After automated
washing and staining, absolute values of expression
were calculated and normalised from the scanned array
by using Affymetrix Microarray Suite (Version 5.0;
Santa Clara, CA, USA). The Affymetrix RNA micro-
rraywas performed by Light Laboratories (Dr E Smith),
University of Leeds using standard procedures.
Gene expression analysis for individual genes was
performed by reverse transcription-PCR (RT-PCR).
One microgram of RNA was reverse transcribed using
Reverse Transcription Systems and oligo dT primers
(Promega) according to the manufacturer’s protocols.
One microlitre of the cDNA obtained was then used as
template for PCR amplification. Primer sequences and
conditions are detailed in Supplementary Table 2,
which can be viewed online at http://erc.endo-
crinology-journals.org/supplemental/. As a control,
the GAPDH primers used were: 5 0-AAGGTGAA
GGTCGGAGTCAACG-3 0 and 5 0-CAGCCTTCTCCA
TGGTGGTGAA-3 0, resulting in a PCR product of
319 bp. PCR products were visualised on 2% agarose
gels stained with ethidium bromide.www.endocrinology-journals.orgStatistical analysis
Fisher’s exact test was used as appropriate. P values of
!0.05 were taken as statistically significant.Results
Identification and evaluation of differentially
expressed genes after demethylation of three
neuroblastoma cell lines
Following treatment with the demethylating agent
5-aza-dC (5 mmol/l) for 5 days to reactivate the
epigenetically silenced/downregulated genes, gene
expression patterns pre- and post-treatment were
compared using Gene ExpressionMicroarrays (Affyme-
trix HG-U133A) in three neuroblastoma cell lines
(SK-N-F1, SK-N-BE and SK-N-DZ). Candidate
epigenetically silenced genes were prioritised for
possible further investigation if a) they were known to
be expressed in normal adrenal tissue (http://genome.
ucsc.edu/cgi-bin/hgGateway), b) they were not located
on the X chromosome or known to be imprinted, c) there
was a CpG island proximal to the transcriptional start site
that contained a predicted promoter sequence and d)
treatment with 5-aza-dC was associated with aO2-fold
upregulation, in at least two cell lines (or one cell line for
genes previously implicated in human tumourigenesis).Evaluation of candidate gene selection criteria
for genes known to be epigenetically inactivated
in neural crest tumours
Previously, we identified promoter region methylation
in neuroblastoma and phaeochromocytoma for DcR1,
DcR2, DR4, CASP8 and TSP1. To evaluate our
candidate gene selection criteria, we investigated the
correlation between promoter methylation status and
fold changes in expression for these five genes in the
three cell lines. Generally, there was a good correlation
e.g. DcR1, which is methylated in SK-N-F1 and
SK-N-DZ, but not in SK-N-BE was associated with
microarray expression changes of 2.77-, 2.47- and
0.47-fold respectively. If the proposed selection
criteria had been applied to these five genes then four
(DcR1, DcR2, DR4 and CASP8) would have been
selected for further analysis. We then applied our
criteria and selected 27 candidate genes for further
investigation (Table 1). Prior to performing 5 0 CpG
island promoter methylation, we evaluated the validity
of the gene expression microarray analysis results for
10 genes (K19, Stannin (SNN), RASD1, actin-related
protein 2/3 complex, sub unit 4 (ARPC4), protein
tyrosine kinase 2 beta (PTK2B), transcription factor779
Table 1 Data from microarray analysis showing candidate genes with greatest fold changes in expression after treatment with
5-aza-dC. Genes in bold were already known to have a role in the pathogenesis of neuroblastomas
Affy ID Gene Gene name SK-N-F1 SK-N-BE SK-N-DZ
201650_at KRT19 Keratin 19 1.95 3.73 63.71
218033_s_at SNN Stannin 3.76 1.00 50.50
206215_at OPCML Opioid binding protein 20.52 3.52 0.26
223467_at RASD1 Activator of G protein signalling (AGS1) 19.64 3.03 0.65
217817_at ARPC4 Actin-related protein 2/3 complex, sub unit 4 11.99 1.02 3.98
203110_at PTK2B Protein tyrosine kinase 2 beta 2.73 10.95 2.02
205688_at TFAP4 Transcription factor AP-4 2.45 7.45 4.96
201367_s_at ZFP36L2 Zinc finger protein 36, C3H type-like 2 2.98 2.96 8.71
201167_x_at ARHGDIA r GDP dissociation inhibitor (GDI) a 5.51 1.50 3.88
231248_at CST6 Cystatin E/M 2.73 2.5 5.62
202062_s_at SEL1L Suppressor of lin-12-like 2.64 2.97 5.12
219922_s_at LTBP3 Latent-transforming growth factor b-binding
protein 3
0.82 3.60 5.17
209427_at SMTH Smoothelin 2.91 2.59 3.88
205346_at ST3GAL2 ST3 b-galactoside a-2,3-sialyltransferase 2 3.77 1.43 3.71
201015_s_at JUP Junction plakoglobin/CTNNG 1.44 3.08 3.50
209878_s_at RELA v-rel reticuloendotheliosis viral oncogene
homologue A
1.73 3.32 2.74
209905_at HOXA9 Homeobox A9 0.94 2.71 4.13
204911_s_at TRIM3 Tripartite motif-containing 3 2.07 1.49 4.09
217250_s_at CHD5 Chromodomain helicase DNA -binding protein 5 0.06 3.36 3.9
208325_s_at PRKA2R A kinase (PRKA) anchor protein 13 0.85 3.94 2.30
202588_at AK1 Adenylate kinase 1 2.43 1.53 2.79
203729_at EMP3 Epithelial membrane protein 3 2.11 2.94 1.61
208997_s_at UCP2 Uncoupling protein 2 2.09 1.79 2.48
207740_s_at NUP62 Nucleoporin 62 kDa 2.39 0.93 2.82
222650_s_at SLC2A4 SLC2A4 regulator 1.14 2.38 2.44
207540_s_at SYK Spleen tyrosine kinase 0.33 3.76 0.78
207714_s_at SERPINH1 Heat shock protein 47 2.85 1.58 1.59
221666_s_at TMS1 Target of methylation-induced silencing 1 1.27 1.41 20.08
201781_s_at AIP Aryl hydrocarbon receptor-interacting
protein
1.01 0.86 2.29
C D E Margetts et al.: Evaluation of a functional epigenetic approachAP-4 (TFAP4), Zinc finger protein 36, C3H type-like 2
(ZFP36L2), ARGHDIA, suppressor of lin-12-like
(SEL1) and latent-transforming growth factor
b-binding protein 3 (LTBP3)) by RT-PCR analysis
before and after 5-aza-dC treatment in each of the three
neuroblastoma cell lines. In each case, expression was
consistent with the results of microarray analysis (data
not shown).
5 0 CpG methylation status for candidate
epigenetically inactivated genes
After applying the proposed selection criteria, 21
candidate ‘novel epigenetically silenced TSGs’ were
selected according to the strict criteria (upregulated in
two or more cell lines) and a further seven genes
previously reported to be methylated in other tumour
types and upregulated in at least one cell line were
selected for further analysis.
The methylation status of the 5 0 promoter region
CpG island was determined by direct sequencing of780bisulphite-converted DNA. Out of the 21 candidate
novel phaeochromocytoma TSGs, 19 (excepting
KRT19 and CST6) were completely unmethylated in
the three neuroblastoma cell lines and in adult normal
adrenal DNA. Sequencing of the Keratin 19 (KRT19),
5 0 CpG island revealed heavy methylation in all three
cell lines (22/29, 25/29 and 29/29 CpG dinucleotides
examined were methylated in SK-N-F1, SK-N-BE and
SK-N-DZ respectively). However, the normal adrenal
DNA also showed a similar pattern of CpG methyl-
ation (24/29 CpG dinucleotides methylated). Direct
bisulphite sequencing of CST6 (Cystatin M) 5 0
promoter region revealed methylated CpGs in all
three neuroblastoma cell lines (data not shown). The
CpG island methylation was also detected in four
additional cell lines examined. To confirm the results
of the direct sequencing, cell line and normal adrenal
DNA was subcloned and 10 clones for each cell line
were sequenced. Consistent with the results of direct
sequencing, CpG methylation was detected in cell lineswww.endocrinology-journals.org
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was no correlation between the extent CST6 CpG
island methylation and upregulation of CST6
expression after 5-aza-dC treatment. We then pro-
ceeded to analyse CST6 CpG island methylation in
20 primary tumours (10 neuroblastomas and 10 phaeo-
chromocytomas). None of the tumours showed
significant promoter methylation.
We then analysed the seven genes (OPCML,
Junction plakoglobin (JUP), HOXA9, EMP3, SYK,
HSP47 and TMS1) that a) had previously been shown
to have be implicated in human tumourigenesis and b)
demonstrated a O2-fold increase in expression after
demethylation in at least one of three neuroblastoma
cell lines. The promoter methylation status of OPCML,
JUP, HOXA9, EMP3, SYK, HSP47 and TMS1 was
analysed by previously published MSP primers in cell
lines and in up to 33 phaeochromocytomas and 19
neuroblastomas (see Fig. 1 and Table 3). Three genes
(HSP47, OPCML and HOXA9) demonstrated frequent
(O10%) CpG island methylation in phaeochromo-
cytoma tumours, but methylation of EMP3, although
very frequent in neuroblastoma, was rare in phaeo-
chromocytoma. Two CpG islands were examined for
HSP47 methylation, one in the 5 0 flanking region of
HSP47 that encompasses a promoter and the second
region around its transcriptional start site (Yang et al.
2007). In agreement with this previous study, similar
patterns of methylation were seen in the two regions,Figure 1 Methylation-specific PCR (MSP) of OPCML, CTNNG,
HOXA9, EMP3, SYK, HSP47(a), HSP47(b) and TMS1 in
neuroblastoma and phaeochromocytoma tumours. Bisulphite-
modified DNA was amplified with primers specific for
unmethylated (U) and methylated (M) DNA. Sample number
above lane. NA, normal adrenal DNA. Sizes of the PCR
products are indicated by arrows, U for unmethylated and M for
methylated respectively. Positive control is Sss1-treated DNA.
www.endocrinology-journals.orgalthough the promoter region showed a higher
methylation frequency (90 and 52% in neuroblastoma
and phaeochromocytoma tumours respectively; see
Table 2). Methylation of EMP3 was relatively specific
for neuroblastoma tumours (68 vs 6%, PZ0.000006),
whereas the frequency of HOXA9 promoter methyl-
ation was similar in the two tumour types. TMS1 and
CTNNG displayed lower frequencies (!10%) of CpG
island promoter methylation in phaeochromocytoma
tumours and no promoter region methylation was
detected in cell lines or primary tumours at SYK
(Table 3).
No association was detected between methylation at
OPCML, HOXA9 or HSP47 in individual tumours.
There was also no association between methylation at
OPCML or HSP47 and methylation as CASP 8 orHIC1
(Margetts et al. 2005). To analyse whether the different
subtypes of neural crest tumours showed different
levels of methylation, we combined data from the
current study with additional data reported previously
for FLIP, TSP1, DcR1, DcR2, DR4, DR5, CASP8 and
HIC1 (Margetts et al. 2005) and estimated the mean
percentage of loci methylated in each tumour sample.
There were no significant differences in the mean
percentage of loci methylated among neuroblastoma
(mean 34.3%), VHL phaeochromocytoma (mean
26.8%) and sporadic phaeochromocytoma (mean
27.4%). We did not find any evidence that a particular
gene was differentially methylated in VHL and
sporadic phaeochromocytomas. To determine whether
there was evidence for a subset of tumours with a CpG
island methylator phenotype (CIMP), the distribution
of number of methylated loci per tumour was
compared with that expected from a Poisson distri-
bution. However, there were no significant differences
between the observed and expected distributions
(PZ0.3751).Discussion
Phaeochromocytoma and neuroblastoma are both
derived from the neural crest and there are overlaps
between the regions of allele loss and patterns of TSG
methylation observed in the two tumour types. In the
absence of a human phaeochromocytoma cell line, we
analysed gene expression changes following treatment
with a demethylating agent in three neuroblastoma cell
lines. Such functional epigenomic screens have proven
to be a successful strategy to identify epigenetically
inactivated TSGs in a number of different tumour types
including oesophageal, pancreatic and prostate (Yama-
shita et al. 2002, Sato et al. 2003, Lodygin et al. 2005).781
Table 2 Summary of gene-specific methylation data in VHL-associated and sporadic phaeochromocytomas and neuroblastoma
tumours
Phaeochromocytoma (% methylated)
All VHL Sporadic
Neuroblastoma
tumours (% methylated)
OPCML 12 (4/33) 10.5 (2/19) 14.3 (2/14) 10.5 (2/19)
CTNNG 3 (1/33) 0 (0/19) 7.1 (1/14) 10.5 (2/19)
HOXA9 17.2 (5/29) 25 (4/16) 7.7 (1/13) 22.2 (4/18)
EMP3 6.1 (2/33) 5.3 (1/19) 7.1 (1/14) 68.4 (13/19)
SYK 0 (0/29) 0 (0/16) 0 (0/13) 0 (0/18)
HSP47 (A) 36.4 (12/33) 36.8 (7/19) 35.7 (5/14) 68.4 (13/19)
HSP47 (B) 51.5 (17/33) 52.6 (10/19) 50 (7/14) 89.5 (17/19)
TMS1 6.9 (2/29) 0 (0/16) 15.4 (2/13) 16.7 (3/18)
Data are percentages and numbers of tumour samples analysed. Methylation of EMP3 and HSP47 (A) and HSP47 (B) was
significantly more frequent in neuroblastomas than phaeochromocytomas (PZ0.001, PZ0.02 and PZ0.005 respectively).
C D E Margetts et al.: Evaluation of a functional epigenetic approachIn addition, using this strategy in RCC cell lines, we
identified HAI-2/SPINT2 as a novel epigenetically
inactivated RCC TSG (Morris et al. 2005).
Although our selection criteria for investigating
‘candidate epigenetically silenced TSGs’ would be
expected to result in some false negative prediction, the
major problem we encountered was the absence of
promoter region methylation in many of the genes we
analysed. In addition, two genes that did show
evidence of promoter methylation in neuroblastoma
cell lines did not prove to be methylated in primary
tumours. Whilst these results were disappointing, they
are not unique to neuroblastoma cell lines. Thus, in a
similar study of four RCC cell lines, we identified
SPINT2 as a novel epigenetically inactivated renal
TSG. However, analysis of a further 60 genes that were
differentially expressed after demethylation revealed
that only six (four of which had been reported
previously) demonstrated primary tumour-specific
promoter methylation (Morris et al. 2008). Thus, this
approach has a relatively low specificity for identifying
methylated TSGs. Analysis of a larger number of genes
might have led to the identification of novel TSGs, but
reducing the stringency of the selection criteria would
also probably further lower specificity. A more
effective plan of investigation might be to combine
‘functional epigenomics’ experiments with strategies
to directly identify methylated DNA (e.g. MeDIP), as
this should help exclude genes whose expression is
upregulated after demethylation but do not demon-
strate promoter methylation (Wilson et al. 2006).
Nevertheless, it is possible that candidate TSGs that are
unmethylated but upregulated by demethylation may
prove to be downstream of epigenetically inactivated
TSGs. Thus, we used the Oncomine (http://www.
oncomine.org/) data analysis tool to interrogate gene782expression data reported by Asgharzadeh et al. (2006)
for 19 genes that were upregulated by demethylation
but did not show detectable CpG methylation (SNN,
RASD1, ARPC4, PTK2B, TFAP4, ZFP36L2, ARHG-
DIA, suppressor of lin-12-like (SEL1L), LTBP3,
smoothelin (SMTH), ST3 b-galactoside a-2,3-sialyl-
transferase 2 (ST3GAL2), v-rel reticuloendotheliosis
viral oncogene homologue A (RELA), tripartite motif-
containing 3 (TRIM3), chromodomain helicase
DNA -binding protein 5 (CHD5), PRKA2R, AK1,
UCP2, NUP62, SLC2A4). Out of 19 genes, 4
(adenylate kinase 1; AK1, TFAP4, SNN and SEL1L)
were differentially expressed levels between relapsing
and non-relapsing tumours. In addition, CHD5 has
been identified as a candidate 1p36 neuroblastoma
TSG (Bagchi et al. 2007).
There was a higher frequency of promoter methyl-
ation in primary tumours among the seven genes that
had been previously implicated in human tumouri-
genesis and were selected according to the less strict
criteria (upregulated in one or more cell lines). Three
of these genes, HSP47, HOXA9 and OPCML were
methylated in O10% of phaeochromocytomas.
Both heat-shock protein 47 (HSP47) and OPCML
map to 11q (11q13.5 and 11q25 respectively) and
chromosome 11q allele loss is frequent in both tumour
types (Yokogoshi et al. 1990, Sun et al. 2006, George
et al. 2007). HSP47 encodes a collagen-specific
molecular chaperone and is essential for the production
and maturation of collagens I and IV (Sauk et al. 2005).
Type I collagen negatively regulates cell proliferation
and is deficient in aggressive neuroblastoma tumours
(Yang et al. 2004). Previously, expression of HSP47
was reported to be upregulated after treatment with
5-aza-dC in the neuroblastoma cell line NB2-W-S
and promoter region methylation was detected inwww.endocrinology-journals.org
Table 3 Individual tumour–methylation patterns
Gene
Tumour
type and
number OPCML CTNNG HOX9A EMP3 SYK HSP47(A) HSP47 (B) TMS1 MI
PV 03 U U U U U U M U 0.125
PV 04 U U U U U M M U 0.25
PV 05 U U M U U M M U 0.375
PV 06 U U U U U U U U 0
PV 07 U U U U U U M U 0.125
PV 08 U U U U U U U U 0
PV 09 U U U U U M M U 0.25
PV 10 U U U U U M M U 0.25
PV 11 U U ND U ND U U ND 0
PV 12 U U ND U ND M M ND 0.25
PV 13 U U M U U U U U 0.125
PV 15 U U U U U U U U 0
PV 16 U U U U U M M U 0.25
PV 17 U U M U U U U U 0.125
PV 18 U U U U U U U U 0
PV 19 M U U U U U U U 0.125
PV 21 U U M U U U U U 0.125
PV 22 M U ND U ND U M ND 0.25
PV 23 U U U M U M M U 0.375
PS 03 U M M M U M M M 0.75
PS 05 M U U U U U U U 0.125
PS 06 M U U U U M M U 0.375
PS 07 U U U U U U U M 0.125
PS 08 U U U U U U U U 0
PS 09 U U U U U U M U 0.125
PS 11 U U ND U ND U U ND 0
PS 12 U U U U U M M U 0.25
PS 13 U U U U U U U U 0
PS 14 U U U U U U U U 0
PS 15 U U U U U M M U 0.25
PS 16 U U U U U M M U 0.25
PS 17 U U U U U U M U 0.125
PS 18 U U U U U U U U 0
NB 01 U U M M M M ND 0.67
NB 03 U M U U U U M U 0.25
NB 04 U U U U U U M U 0.125
NB 05 U U U U U U M U 0.125
NB 06 U U M M U M M U 0.5
NB 07 U U U M U M M M 0.375
NB 08 U U U U U U U U 0
NB 09 U U U M U M M U 0.375
NB 10 U U U M U M M U 0.375
NB 11 M U U M U M M U 0.5
NB 12 U M U U U U M U 0.25
NB 13 U U U M U M M U 0.375
NB 14 U U U M U M M U 0.375
NB 15 U U U M U M M U 0.375
NB 16 U U U M U M M U 0.375
NB 17 U U M M U M M M 0.625
NB 18 U U M M U M M M 0.625
NB 19 U U U U U U U U 0
NB 20 M U ND M ND M M ND 0.8
NB, neuroblastoma; PS, sporadic phaeochromocytoma; PV, VHL, associated phaeochromocytoma; U, unmethylated; M,
methylated; ND, not determined (failed); MI, methylation index (number of methylated genes/number genes analysed).
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toma tumours analysed (Yang et al. 2004). In addition,
expression of HSP47 correlated with that of collagen I
and IV. We have confirmed and extended the analysis
of HSP47 promoter methylation in neuroblastoma and
demonstrated that the HSP47 promoter is methylated
in w50% of phaeochromocytomas.
HOXA9 promoter region methylation was detected
in about one-fifth of neuroblastoma and phaeochromo-
cytomas. Several Hox genes have been reported to be
methylated in human cancers, e.g. HOXB13 and
HOXA5, in renal and breast cancer respectively
(Okuda et al. 2006, Piotrowski et al. 2006). HOXA9
promoter methylation was identified previously in lung
cancer (Rauch et al. 2007) and in neuroblastoma
(Alaminos et al. 2004), but not in phaeochromo-
cytoma. Previously, we found significant differences in
the frequency of HIC1 and CASP8 methylation
between VHL-associated and sporadic phaeochromo-
cytomas, but in this study we did not identify any
further differentially methylated genes.
OPCML (OPCML/cell adhesion molecule-like)
encodes a member of the IgLON subfamily in the
immunoglobulin protein superfamily and was identified
as a candidate TSG following the identification of
extensive promotermethylation in ovarian cancer (Sellar
et al. 2003). Ectopic expression of the OPCML gene
product suppressed cell growth in vitro and tumour
growth in vivo in nude mice models. Promoter
methylation associated silencing of OPCML has also
been demonstrated in hepatocellular carcinomas (Liu
et al. 2006) and gliomas and other brain tumours
(including medulloblastomas) (Reed et al. 2007). To
our knowledge, OPCML promoter methylation has not
previously been reported in neuroblastoma or
phaeochromocytoma.
EMP3 is a peripheral myelin protein involved in cell
proliferation and cell–cell interactions. Previously
EMP3 expression was reported to be downregulated
in glioma and neuroblastoma tumours, and EMP3
promoter methylation was detected in 24% of
neuroblastomas (Alaminos et al. 2005). However,
although we confirmed frequent EMP3 promoter
methylation in neuroblastoma, EMP3 methylation did
not appear to make a significant contribution to
phaeochromocytoma tumourigenesis.
Infrequent, or absent, promotermethylationwas found
for CTNNG (g-catenin, also known as JUP) and SYK in
phaeochromocytoma. Although Amitay et al. (2001)
reported reduced expression of CTNNG in 9/20 neuro-
blastoma tumours, we observed promoter methylation in
only 11% of neuroblastoma tumours and did not detect
promoter methylation in the cell lines that demonstrated784an increase expression of CTNNG after 5-aza-dC
treatment. This suggests that promoter methylation of
CTNNG does not play a large role in its regulation of
expression in neural crest tumours. SYK (spleen tyrosine
kinase) and TMS1 (also known as ASC, apoptosis speck-
like protein containing CARD) have been reported to be
methylated in 60 and 80% of neuroblastoma cell lines
respectively (Alaminos et al. 2004), our results suggest
that methylation is less frequent in neuroblastoma
primary tumours and is infrequent (!10%) in phaeo-
chromocytoma. The CIMP methylator phenotype is
well described in a subset of colorectal cancers
(Weisenberger et al. 2006). However, we did not find
evidence of a CIMP subgroup in neural crest tumours
and mean methylation index did not differ between
neuroblastomas, VHL and sporadic phaeochromoctro-
mas. Our findings demonstrate that many genes that are
methylated in neuroblastoma are also methylated in
phaeochromocytoma. Identification of methylated
genes in neural crest tumours will provide potential
biomarkers and can provide insights into the molecular
pathogenesis of tumour development in these disorders.Declaration of interest
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